These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31488153)

  • 1. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
    Seremet T; Jansen Y; Planken S; Njimi H; Delaunoy M; El Housni H; Awada G; Schwarze JK; Keyaerts M; Everaert H; Lienard D; Del Marmol V; Heimann P; Neyns B
    J Transl Med; 2019 Sep; 17(1):303. PubMed ID: 31488153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
    Lee JH; Long GV; Boyd S; Lo S; Menzies AM; Tembe V; Guminski A; Jakrot V; Scolyer RA; Mann GJ; Kefford RF; Carlino MS; Rizos H
    Ann Oncol; 2017 May; 28(5):1130-1136. PubMed ID: 28327969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
    Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
    Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
    Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
    JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.
    Lee JH; Menzies AM; Carlino MS; McEvoy AC; Sandhu S; Weppler AM; Diefenbach RJ; Dawson SJ; Kefford RF; Millward MJ; Al-Ogaili Z; Tra T; Gray ES; Wong SQ; Scolyer RA; Long GV; Rizos H
    Clin Cancer Res; 2020 Aug; 26(15):4064-4071. PubMed ID: 32321716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma.
    Lee RJ; Gremel G; Marshall A; Myers KA; Fisher N; Dunn JA; Dhomen N; Corrie PG; Middleton MR; Lorigan P; Marais R
    Ann Oncol; 2018 Feb; 29(2):490-496. PubMed ID: 29112704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy.
    Marsavela G; Lee J; Calapre L; Wong SQ; Pereira MR; McEvoy AC; Reid AL; Robinson C; Warburton L; Abed A; Khattak MA; Meniawy TM; Dawson SJ; Sandhu S; Carlino MS; Menzies AM; Scolyer RA; Long GV; Amanuel B; Millward M; Ziman MR; Rizos H; Gray ES
    Clin Cancer Res; 2020 Nov; 26(22):5926-5933. PubMed ID: 33067256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
    Ashida A; Sakaizawa K; Uhara H; Okuyama R
    Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
    Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
    J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
    Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
    Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study.
    Herbreteau G; Vallée A; Knol AC; Théoleyre S; Quéreux G; Varey E; Khammari A; Dréno B; Denis MG
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab.
    Forthun RB; Hovland R; Schuster C; Puntervoll H; Brodal HP; Namløs HM; Aasheim LB; Meza-Zepeda LA; Gjertsen BT; Knappskog S; Straume O
    Sci Rep; 2019 Nov; 9(1):17471. PubMed ID: 31767937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
    Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
    Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report.
    Calapre L; Warburton L; Millward M; Gray ES
    BMC Cancer; 2019 Nov; 19(1):1109. PubMed ID: 31727009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma.
    Calapre L; Giardina T; Robinson C; Reid AL; Al-Ogaili Z; Pereira MR; McEvoy AC; Warburton L; Hayward NK; Khattak MA; Meniawy TM; Millward M; Amanuel B; Ziman M; Gray ES
    Mol Oncol; 2019 Feb; 13(2):171-184. PubMed ID: 30312528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
    Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
    Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting.
    Rowe SP; Luber B; Makell M; Brothers P; Santmyer J; Schollenberger MD; Quinn H; Edelstein DL; Jones FS; Bleich KB; Sharfman WH; Lipson EJ
    Mol Oncol; 2018 Oct; 12(10):1661-1672. PubMed ID: 30113761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.